Well considering where PETX was before it fell it's still a dip, lol. The appetite drug that got delayed is still gonna be approved in 2017. Here's the article when it fell.
Shares of Aratana Therapeutics Inc. PETX, +5.26% tumbled 9.1% in premarket trade Monday, after the pet therapeutics company disclosed that the Center for Veterinary Medicine requested more information about its appetite stimulation drug. Aratana said the request is related to the company's post-approval supplement request to transfer the manufacturing of Tentyce to a new vendor. The company said it now expects Entyce to be commercially available by late 2017. The stock has more than doubled over the past 12 months through Friday, while the S&P 500 SPX, +0.36% has gained 22%.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.